The main features of NASH pathology in metabolic models, i.e., steatosis, mild inflammation, and mild fibrosis have all been found to be improved by treatments with FGF21, as well as FGF19 and analogues thereof (86, 87, 107, 112) which may partly be driven by a decrease in BW. This evidence concerns the gene FGF19 and metabolic dysfunction-associated steatohepatitis.